- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Lupus nephritis
- Meeting Date: March 2026
- Public Summary Document (PSD) March 2026 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2026 PBAC Meeting - (DOCX)
Obinutuzumab – March 2026
Solution for I.V. infusion 1000 mg in 40 mL,
Last updated
11 March 2026